Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)

Trial Profile

Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Moxifloxacin (Primary) ; Azithromycin; Cefotaxime; Ceftriaxone; Clarithromycin; Erythromycin; Hydrocortisone; Levofloxacin
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms AD-SCAP; REMAP-CAP
  • Most Recent Events

    • 09 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top